Name: Lipid Disorder Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3337
Price: 4350 USD
Availability: InStock

Lipid Disorder Treatment Market Analysis, Size and Forecast 2023-2030

Lipid Disorder Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Lipid Disorder Treatment Market is segmented By Drug Class (Atorvastatin, Rosuvastatin, Fluvastatin, Simvastatin, Pravastatin, Others), By Indication (Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

<h2>Market Overview</h2>

<blockquote>
The Global Lipid Disorder Treatment Market is expected to grow at a high&nbsp;CAGR during the forecasting period (2023-2030).
</blockquote>

Lipid disorders refer to a broad spectrum of metabolic conditions that affect blood lipid levels. They are characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of cardiovascular disease. There are several easy ways to lower the lipid disorder levels (LDLs), including avoiding foods that are high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and avoiding smoking. Statins are the commonly prescribed treatment for lipid disorders.

&nbsp;

<h2>Market Dynamics</h2>

The increase in the adoption of sedative lifestyles by consumers has rapidly increased various lifestyle diseases around the globe. The presence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will further drive the market. According to information published by a World Health Organization report, a third of ischemic heart disease is related to high cholesterol levels. Moreover, smoking and drinking have also lead to a rising prevalence of lipid disorders, which further drives the growth of the lipid disorder treatment market during the forecast period.

Changing Lifestyle and Hectic Schedule

Lipid disorders are mainly caused due to obesity and high cholesterol. Obesity has become a prominent problem among a large chunk of the global population. The changing lifestyle and the increased use of alcohol and junk food have triggered obesity among a considerable populace. This will further augment the global lipid disorder treatment market during the forecast period.

Increase in Level of Triglyceride to Drive the Market Growth

The market for lipid disorder treatment is impacted by developing occurrences of disorders related to LDL and a rise in triglyceride levels in the human body. Lipid disorders are common among the working-class population around the globe, which is caused due to fewer body developments, failed weight control plans, immobile activity, and poor lifestyle and habits, such as excessive smoking and drinking that bring about a rise in cholesterol levels.

COVID-19 Impact Analysis

COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has directly impacted the manufacturers&#39; supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the lockdown policies have resulted in tremendous losses for the lipid disorder treatment market. Thus, this aspect may harm the growth of the lipid disorder treatment market to a certain extent during the forecast period.

<h2>Segment Analysis</h2>

Based on the drug type, the lipid disorder treatment market has been classified into atorvastatin, rosuvastatin, fluvastatin, &nbsp;simvastatin, pravastatin, and others.

Atorvastatin to Witness Increased Demand for Lipid Disorder Treatment

The increasing risk of lipid disorders has forced pharmaceutical companies to initiate drug enhancement, new drugs development, and conduct phase trials of these drugs on a large scale. Statins are considered highly effective in lowering the rate of cardiovascular events. many companies are focusing on the mass production of atorvastatin as they are highly effective low-density lipoprotein lowering agents, LDL being the root cause of lipid disorders and associated heart diseases. The consumption of atorvastatin drugs is expected to grow significantly during the forecast period

The distribution channel segment is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Retail Pharmacies segment to boost growth during the forecast period

The retail pharmacies segment accounted for the largest market share due to the high number of retail pharmacies across the globe. Online pharmacies will witness rapid growth over the forecast period because of rapid digitalization and convenience.

&nbsp;

<h2>Geographical Analysis</h2>

Based on geography,&nbsp;the study analyzes the lipid disorder treatment in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East &amp; Africa.

North America leads the global market throughout the forecast period

North America accounted for the largest share in the global lipid disorder treatment market during the forecast period. The rising prevalence of lipid disorders, cardiovascular diseases, and rising health awareness are factors driving the market in the North American region. Europe accounted for the second-largest regional market. The established presence of pharmaceutical companies and rising awareness and prevalence of lipid disorders in the region are some of the factors that are expected to boost the market growth during the forecast period. The Asia Pacific is expected to showcase the highest growth potential for the lipid disorder treatment market during the forecast period. An increase in geriatric population base with high vulnerability to metabolic disorders, sedentary lifestyle, growing prevalence of lipid disorders is some factors promoting lipid disorder treatment market growth in the Asia Pacific.

<h2>Competitive Landscape</h2>

The lipid disorder treatment market is highly competitive, owing to the presence of big brands. The key lipid disorder treatment players which are contributing to the growth of the global market include Mylan Pharmaceuticals, Kowa Pharmaceuticals America, Inc., Teva Pharmaceuticals, Pfizer, Inc., Novartis AG, AstraZeneca Plc, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Emcure Pharmaceuticals Ltd., Wockhardt Limited, and Merck &amp; Co. among others.

Pfizer Inc. 

Overview: Pfizer Inc. (Pfizer) is one of the leading biopharmaceutical companies across the globe. It is primarily engaged in the research, development and manufacture of drugs and healthcare products. The Company operates its business through two business segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). EH includes branded generics, legacy brands, biosimilars generic sterile injectable products, and infusion systems. EH also includes a research and development organization, as well as its contract manufacturing business. IH emphasises on development and commercialization of medicines and vaccines. IH therapeutic areas include internal medicine, oncology, vaccines, inflammation and immunology, rare diseases and consumer healthcare. Its brands include Prevnar 13, Eliquis, Xeljanz, Celebrex, Lipitor, Viagra and Pristiq.

&nbsp;Product Portfolio: The company&#39;s product portfolio consists of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13 Lyrica Eliquis Enbrel Becosules Gelusil and Corex range of products.

Why Purchase the Report?

<ul>
	<li>Visualize the yeast extract market segmentation composition by drug type, distribution channel, indication, and region, highlighting the critical commercial assets and players.</li>
	<li>Identify commercial opportunities in the yeast extract market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of yeast extract market - level 3 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global lipid disorder treatment market report would provide access to an approx. 60 market data table, 61 figures and 180 pages. 

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/frontotemporal-disorders-treatment-market">Frontotemporal Disorders Treatment Market</a>

<a href="https://www.datamintelligence.com/research-report/pigmentation-disorder-treatment-market">Pigmentation Disorder Treatment Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Drug Class</li>
		<li>Market Snippet by Indication</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing prevalence of LDL and triglyceride associated lipid disorders</li>
				<li>Growing prevalence of cardiovascular diseases</li>
				<li>Changing eating habits and sedentary lifestyle</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Stringent Regulatory Requirements</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Value Chain Analysis</li>
		<li>PEST Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
		<li>Patent Trends</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Drug Class</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment</li>
		<li>Market Attractiveness Index, By Drug Class Segment
		<ol>
			<li>Atorvastatin*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Rosuvastatin</li>
			<li>Fluvastatin</li>
			<li>Simvastatin</li>
			<li>Pravastatin</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Indication</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment</li>
		<li>Market Attractiveness Index, By Indication Segment
		<ol>
			<li>Familial Combined Hyperlipidemia*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Familial Defective Apolipoprotein</li>
			<li>Familial Dysbetalipoproteinemia</li>
			<li>Familial Hypertriglyceridemia</li>
			<li>Heterozygous Familial Hypercholesterolemia</li>
			<li>Other Indications</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Distribution Channel</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment</li>
		<li>Market Attractiveness Index, By Distribution Channel Segment
		<ol>
			<li>Hospital Pharmacy*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Retail Pharmacy</li>
			<li>Online Pharmacy</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region</li>
		<li>Market Attractiveness Index, By Region</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3>Global Lipid Disorder Treatment Market- Company Profiles</h3>

	<ol>
		<li>Pfizer*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Merck &amp; Co.</li>
		<li>Emcure Pharmaceuticals Ltd.</li>
		<li>Ranbaxy Laboratories Ltd.</li>
		<li>AstraZeneca</li>
		<li>Teva Pharmaceuticals</li>
		<li>Mylan Pharmaceuticals, Inc.</li>
		<li>Kowa Pharmaceuticals America, Inc.</li>
		<li>Novartis AG</li>
		<li>Glenmark Pharmaceuticals Ltd.</li>
		<li>Sun Pharmaceuticals Industries Ltd.</li>
		<li>Wockhardt Limited(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>Premium Insights</h3>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<ul style="list-style-type:square">
</ul>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables 
Table 1 Global Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 2 Global Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 3 Global Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 4 Global Lipid Disorder Treatment Market Value, By Region, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 5 North America Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 6 North America Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 7 North America Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 8 North America Lipid Disorder Treatment Market Value, By Country, 2018-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 9 South America Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 10 South America Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 11 South America Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 12 South America Lipid Disorder Treatment Market Value, By Country, 2018-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 13 Europe Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 14 Europe Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 15 Europe Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 16 Europe Lipid Disorder Treatment Market Value, By Country, 2018-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 17 Asia Pacific Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 18 Asia Pacific Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 19 Asia Pacific Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 20 Asia Pacific Lipid Disorder Treatment Market Value, By Country, 2021, 2025 &amp; 2029 (US$ Million) 
Table 21 The Middle East &amp; Africa Lipid Disorder Treatment Market Value, By Drug Class, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 22 The Middle East &amp; Africa Lipid Disorder Treatment Market Value, By Indication, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 23 The Middle East &amp; Africa Lipid Disorder Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 24 The Middle East &amp; Africa Lipid Disorder Treatment Market Value, By Country, 2021, 2025 &amp; 2029 (US$ Million) 
Table 25 Merck &amp; Co.: Overview&nbsp;&nbsp; &nbsp; 
Table 26 Merck &amp; Co.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 27 Merck &amp; Co.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 28 Emcure Pharmaceuticals Ltd.: Overview&nbsp;&nbsp; &nbsp; 
Table 29 Emcure Pharmaceuticals Ltd.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 30 Emcure Pharmaceuticals Ltd.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 31 Ranbaxy Laboratories Ltd. Overview&nbsp;&nbsp; &nbsp; 
Table 32 Ranbaxy Laboratories Ltd.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 33 Ranbaxy Laboratories Ltd.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 34 AstraZeneca: Overview&nbsp;&nbsp; &nbsp; 
Table 35 AstraZeneca: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 36 AstraZeneca: Key Developments&nbsp;&nbsp; &nbsp; 
Table 37 Pfizer: Overview&nbsp;&nbsp; &nbsp; 
Table 38 Pfizer: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 39 Pfizer: Key Developments&nbsp;&nbsp; &nbsp; 
Table 40 Teva Pharmaceuticals: Overview&nbsp;&nbsp; &nbsp; 
Table 41 Teva Pharmaceuticals: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 42 Teva Pharmaceuticals: Key Developments&nbsp;&nbsp; &nbsp; 
Table 43 Mylan Pharmaceuticals, Inc.: Overview&nbsp;&nbsp; &nbsp; 
Table 44 Mylan Pharmaceuticals, Inc.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 45 Mylan Pharmaceuticals, Inc.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 46 Kowa Pharmaceuticals America, Inc.: Overview&nbsp;&nbsp; &nbsp; 
Table 47 Kowa Pharmaceuticals America, Inc.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 48 Kowa Pharmaceuticals America, Inc.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 49 Novartis AG: Overview&nbsp;&nbsp; &nbsp; 
Table 50 Novartis AG: Product Portfolio 
Table 51 Novartis AG: Key Developments 
Table 52 Glenmark Pharmaceuticals Ltd.: Overview&nbsp;&nbsp; &nbsp; 
Table 53 Glenmark Pharmaceuticals Ltd.: Product Portfolio 
Table 54 Glenmark Pharmaceuticals Ltd.: Key Developments 
Table 55 Sun Pharmaceuticals Industries Ltd.: Overview&nbsp;&nbsp; &nbsp; 
Table 56 Sun Pharmaceuticals Industries Ltd.: Product Portfolio 
Table 57 Sun Pharmaceuticals Industries Ltd.: Key Developments 
Table 58 Wockhardt Limited: Overview&nbsp;&nbsp; &nbsp; 
Table 59 Wockhardt Limited: Product Portfolio 
Table 60 Wockhardt Limited: Key Developments 
List of Figures 
Figure 1 Global Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 2 Global Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 3 Global Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 4 Global Lipid Disorder Treatment Market Share, By Region, 2021 &amp; 2029 (%) 
Figure 5 Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 6 Global Lipid Disorder Treatment Market Y-o-Y Growth, By Drug Class, 2021-2029 (%) 
Figure 7 Atorvastatin: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 8 Rosuvastatin: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 9 Fluvastatin: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 10 Simvastatin: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 11 Pravastatin: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 12 Others: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 13 Global Lipid Disorder Treatment Market Y-o-Y Growth, By Indication, 2021-2029 (%) 
Figure 14 Familial Combined Hyperlipidemia: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 15 Familial Defective Apolipoprotein: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 16 Familial Dysbetalipoproteinemia: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 17 Familial Hypertriglyceridemia: Global Lipid Disorder Treatment Market Value, 2018-2029 
Figure 18 Heterozygous Familial Hypercholesterolemia: Global Lipid Disorder Treatment Market Value, 2018-2029 
Figure 19 Other Indications: Global Lipid Disorder Treatment Market Value, 2018-2029 
Figure 20 Global Lipid Disorder Treatment Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%) 
Figure 21 Hospital Pharmacy: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 22 Retail Pharmacy: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 23 Online Pharmacy: Global Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 24 Global Lipid Disorder Treatment Market Y-o-Y Growth, By Region, 2021-2029 (%) 
Figure 25 North America Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 26 North America Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 27 North America Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 28 North America Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 29 North America Lipid Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 30 South America Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 31 South America Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 32 South America Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 33 South America Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 34 South America Lipid Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 35 Europe Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 36 Europe Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 37 Europe Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 38 Europe Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 39 Europe Lipid Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 40 Asia-Pacific Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 41 Asia-Pacific Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 42 Asia-Pacific Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 43 Asia-Pacific Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 44 Asia-Pacific Lipid Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 45 The Middle East &amp; Africa Lipid Disorder Treatment Market Value, 2018-2029 (US$ Million) 
Figure 46 The Middle East &amp; Africa Lipid Disorder Treatment Market Share, By Drug Class, 2021 &amp; 2029 (%) 
Figure 47 The Middle East &amp; Africa Lipid Disorder Treatment Market Share, By Indication, 2021 &amp; 2029 (%) 
Figure 48 The Middle East &amp; Africa Lipid Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 49 The Middle East &amp; Africa Lipid Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 50 Merck &amp; Co.: Financials 
Figure 51 Emcure Pharmaceuticals Ltd.: Financials 
Figure 52 Ranbaxy Laboratories Ltd.: Financials 
Figure 53 AstraZeneca: Financials 
Figure 54 Pfizer: Financials 
Figure 55 Teva Pharmaceuticals: Financials 
Figure 56 Mylan Pharmaceuticals, Inc.: Financials 
Figure 57 Kowa Pharmaceuticals America, Inc.: Financials 
Figure 58 Novartis AG: Financials 
Figure 59 Glenmark Pharmaceuticals Ltd.: Financials 
Figure 60 Sun Pharmaceuticals Industries Ltd.: Financials 
Figure 61 Wockhardt Limited: Financials 
&nbsp;